Lubin Investment · Blog

Deeply cheap quality stocks: bargain or trap?

2026-06-11 ·

In June 2026, seven companies I score 10/10 on quality trade at under five years of the cash they generate. That is rare, and tempting. But a very low price usually hides a reason. Here is how I separate quality from price, and why I always dig into the market's doubt before drawing conclusions.

The number that makes you salivate, and should make you cautious

Picture a company that brings you 100 dollars of cash a year, offered to you for 110 dollars. You get your stake back in a little over a year, and all the cash in the years after is a bonus. That is, roughly, what the market says about Afya in June 2026: a P/FCF of 1.1.

P/FCF is the share price divided by the free cash flow it generates each year. Free cash flow is the money that truly stays in the bank once every bill is paid (salaries, machines, taxes). A P/FCF of 1.1 means you pay barely more than one year of that cash. The lower the number, the cheaper it is. At this level, we are no longer in cheap territory, we are in abnormally low territory.

And that is exactly what should make you careful. When the market dumps a company this hard, it never does it out of kindness. It is anticipating something: a risk, a threat, cash that will not last. My job as an analyst is to guess what, before getting excited.

Why I judge quality before looking at the price

When I look at a stock, I always separate two questions most people confuse. One: is this a good company? Two, entirely apart: is this the right price? A great company bought too expensive is still a bad investment. A mediocre company, even dirt cheap, stays mediocre. Mixing the two is the number one source of error.

For quality, I do not trust my gut. I run the company through ten concrete financial criteria: is it profitable, are its sales and cash growing, does it buy back its own shares rather than waste money, is its debt manageable, is its return on capital high? Each criterion passed is worth one point. A score of 10 out of 10 means the company ticks all ten boxes, on accounting facts, not on a story.

One criterion I watch closely: Cash ROCE, the return on capital employed measured in cash. In plain terms, for every dollar tied up in the business (plants, inventory, working capital), how much cash the company pulls out each year. A high Cash ROCE means the machine turns little capital into a lot of liquidity: the sign of a business that does not need to swallow money to grow.

The seven 10/10 stocks under 5 years of cash in June 2026

Here is the verified list, from cheapest to least cheap, with their P/FCF. Read it as a list of questions to dig into, not a shopping list.

One thing jumps out: five of the seven names touch insurance or reinsurance one way or another (Universal, RenaissanceRe, Mercury, Selective, plus the risk angle for the rest). That is no accident. It is the first lead to understand why the market doubts.

Why is the market dumping so many insurers?

Insurance is a cyclical business. A company collects premiums, invests the money, and pays claims. When a year is quiet, cash swells, P/FCF collapses, and the stock looks ridiculously cheap. But a single big event (a hurricane, a fire, a wave of claims) can wipe out several years of profit at once. The market knows this. So it refuses to pay the cash of a good year as if it were guaranteed every year.

This is where cyclicality becomes a trap for the untrained eye. An insurer at 3 times its cash is not necessarily three times cheaper than one at 9 times: it may simply be coming off an unusually mild year nobody believes is repeatable. The low P/FCF then reflects a legitimate doubt, not a market error.

On top of that come risks specific to each case. Afya is exposed to a single country, Brazil: its currency, its education regulation, its rates. Universal and Mercury are concentrated in areas highly exposed to catastrophes. SkyWest depends on a few large airlines that subcontract flights to it: losing a contract means losing a chunk of revenue with a stroke of a pen. None of these risks shows up in the quality score, which looks at the accounting past. The price, on the other hand, looks at the future.

Real discount or value trap?

A value trap is a stock that looks cheap on past figures but stays cheap because the future is less rosy than the past. Cash dries up, growth stops, the risk materializes, and the low price was not a bargain, just a warning you failed to hear.

Conversely, a real discount is a good company that is temporarily unloved: the market overreacts to a fear, the cash keeps flowing, and the low price eventually corrects. The whole challenge is telling the two apart, and no ratio does it for you. A low P/FCF is never a bargain in itself: it only is if the quality holds AND the market's doubt is overblown.

That is why the quality score and the price are not enough on their own. A 10/10 tells me the business has been solid. A P/FCF below 5 tells me the market doubts. My work begins there: why does it doubt, and is it right? For a good chunk of these insurers, the doubt is about the durability of cash in a cyclical business. For Afya, about country risk. These are questions I answer case by case, never with an average.

How I actually use this list

I do not treat this list as seven buy orders. I treat it as seven invitations to investigate. For each name, I ask three questions in order: does the 10/10 still hold on the latest figures, or is quality eroding? Is recent cash representative, or inflated by an easy year? And is the risk that justifies the low price already known to everyone, or underestimated?

If you want to dig into a case, you can open its analysis page, for example the RenaissanceRe analysis or the SkyWest one, to see the detail of the ten criteria and the buy price I allow myself. You can also browse my ranking of 10/10 stocks on quality, or the undervalued ones on price, and spot the rare cases where both truly align. And if you want to understand how I score, it is all laid out in my methodology.

What I take away

A P/FCF below 5 on a 10/10 stock is neither a trap nor a bargain by default: it is a starting point. The score tells me the business has been good. The price tells me the market is afraid. My job is to understand the fear before forming a view, and never to confuse cheap with a good deal. Cheap is everywhere. Quality that is cheap and rightly dumped is far rarer. That is exactly what my site helps me sort in a few seconds, stock by stock.

FAQ

What is a P/FCF below 5?

It is a share price worth less than five years of the free cash flow generated each year. In other words, in theory you recover your stake in under five years of cash. That is very cheap, but such a low price almost always hides a reason you need to understand.

Why so many insurers on this list?

Because insurance is cyclical. A quiet year swells cash and crushes the P/FCF, but a single big loss can wipe out several years of profit. So the market refuses to pay the cash of a good year as if it were guaranteed, which keeps P/FCF structurally low.

Is a cheap 10/10 stock always a good deal?

No. The 10/10 judges past quality on accounting facts, not the future. A low price can be a real discount or a value trap if cash dries up. You must always understand why the market doubts before concluding.

What is a value trap?

A stock that looks cheap on past figures but stays cheap because the future is worse: cash falls, growth stops, the risk materializes. The low price was not a bargain, just a warning that was ignored.

How do I separate quality from price?

I score quality on ten objective financial criteria (profitability, growth, buybacks, debt, return on capital). Price I measure separately with the P/FCF. A stock is only interesting if quality holds and the price is low for bad reasons the market has overblown. This is not investment advice.

Analyser une action sur Lubin Investment

About the author

Written by Lubin Danilo, founder of Lubin Investment. A self-taught individual investor, I have analyzed stocks through their fundamentals for several years and invest my own money with this method. I codified it into a tool that judges a company's quality and its price separately, using criteria drawn from the financial literature (Warren Buffett, Michael Mauboussin, Aswath Damodaran).